Phase 2 randomized trial of a moxifloxacin-containing regimen for treatment of smear-positive pulmonary tuberculosis in adults with and without HIV infection

Trial Profile

Phase 2 randomized trial of a moxifloxacin-containing regimen for treatment of smear-positive pulmonary tuberculosis in adults with and without HIV infection

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Mar 2013

At a glance

  • Drugs Ethambutol; Isoniazid; Moxifloxacin; Pyrazinamide; Rifampicin
  • Indications Pulmonary tuberculosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Mar 2013 Lead trial centre (Johns Hopkins University) added as reported by ClinicalTrials.gov record.
    • 04 Apr 2009 Primary endpoint 'Bacteriological eradication rate' has been met.
    • 04 Apr 2009 Results have been reported in the Lancet.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top